MREO: Act Now! Deadline Approaches for Class Action Counsel

Ticker: MREO (Mereo BioPharma Group plc) – NASDAQ-listed clinical-stage biopharmaceutical company focused on rare diseases. This report examines Mereo’s financial profile and current challenges, including an ongoing shareholder class action. We cover dividend policy, leverage, coverage ratios, valuation, and key risks/red flags, concluding with open questions for investors. All information is sourced from company filings, investor materials, or credible financial media.

Dividend Policy & Shareholder Returns

No Dividend History: Mereo has never paid or declared a dividend on its ordinary shares, and it does not anticipate initiating any dividends in the foreseeable future (www.sec.gov). The company’s policy is to retain all available funds to finance R&D and business growth rather than return cash to shareholders (www.sec.gov). Under U.K. law, Mereo can only pay dividends out of distributable reserves, but as a development-stage biotech with cumulative losses, it lacks such reserves. Consequently, MREO’s dividend yield is 0%, and investors’ return prospects hinge entirely on capital appreciation (or depreciation) of the stock.

Investor Takeaway: Shareholders should not expect income from MREO in the near term. Instead, the investment thesis (and risk) centers on the company’s ability to create value through successful drug development and partnerships, rather than through dividend payouts.

Leverage and Debt Maturities

Convertible Notes: Mereo’s balance sheet carries minimal traditional debt, consisting mainly of convertible loan notes issued to fund operations. In a June 2020 private placement, the company raised ~$50.6 million in convertible notes, most of which have since converted to equity. An automatic conversion in mid-2020 exchanged £21.8 million of these notes into equity, subject to ownership caps (www.sec.gov). As of year-end 2022, only £6.2 million in principal remained outstanding and convertible into shares (down from £12.4 million in 2021) (www.sec.gov). These remaining notes carry no fixed maturity date disclosed in filings; they are expected to convert to shares under their terms, which has gradually been occurring.

Novartis Loan Note: In February 2020, Mereo issued a £3.8 million unsecured convertible note to Novartis, related to assets Mereo acquired from Novartis (www.sec.gov). This note was originally set to mature on February 10, 2023, but on that date the parties agreed to an amendment extending maturity to February 10, 2025 (www.sec.gov). Upon extension, Mereo paid the accrued interest in cash and sweetened the deal by issuing Novartis additional equity warrants (2,000,000 ordinary-share warrants exercisable at £0.150 per share through 2028) (www.sec.gov). The conversion price on the Novartis note remained at a fixed £0.265 per ordinary share (equivalent to ~£1.325 per ADS, since each ADS represents five ordinary shares) (www.sec.gov). If Mereo’s stock stays below that price, Novartis may choose not to convert, meaning Mereo would owe the £3.8 million principal at the 2025 maturity. The issuance of new warrants at a much lower strike (£0.150) upon extension suggests a concession to Novartis, perhaps reflecting that the stock was trading well under the original conversion price by early 2023.

No Significant Bank Debt: Notably, Mereo has no outstanding bank loans or term debt. The company previously had a credit facility with Silicon Valley Bank and Kreos Capital, but it repaid that facility in full in 2020 (www.sec.gov). Only some warrants from the former lenders remain outstanding as a legacy of that loan. The absence of secured debt means Mereo does not face near-term debt amortization or significant interest expenses beyond the convertible notes.

Debt Maturity Profile: Given the above, Mereo’s only fixed debt maturity is in Feb 2025 (the Novartis note). The remaining 2020 private placement notes are effectively equity-linked and convertible at the holders’ discretion. Investors should monitor whether the £6.2 million still outstanding converts to shares (which could dilute equity) or if any renegotiation is needed. Overall leverage is low – in substance, Mereo remains largely equity-funded, which is typical for a biotech of its stage.

Cash Flow, Coverage, and Liquidity

No Operating Cash Inflows: Mereo has no approved products and generates no revenue from product sales to date (www.sec.gov). As a result, it consistently operates at a net loss and negative operating cash flow, common for clinical-stage biotechs. The company has financed its activities through external capital: issuances of equity, convertible debt, and warrants have raised ~$183 million (£137.9 million) cumulatively (www.sec.gov). In addition, Mereo received a $50 million upfront payment in 2021 from a partnership with Ultragenyx for its lead drug candidate setrusumab (www.sec.gov). These funds, plus periodic follow-on offerings, have been the lifeblood of Mereo’s R&D operations.

Coverage Ratios: Traditional coverage metrics like interest coverage or Fixed-Charge Coverage are not meaningful for Mereo, since the company’s EBITDA and FFO are negative. There is no EBIT or funds-from-operations to “cover” interest or fixed charges – instead, cash burn is covered by existing cash reserves and new capital raises. Interest expense on the convertible notes is relatively minor in absolute terms (the notes carry fixed interest; for example, accrued interest on the Novartis note was paid off in 2023) (www.sec.gov). Mereo’s strategy has been to maintain a cash runway sufficient to fund operations for a couple of years and then refill via financing or partnerships as needed.

Liquidity and Runway: As of September 30, 2025, Mereo reported cash of $48.7 million, which management estimated was sufficient to fund operations into 2027 under the then-current plans (www.biospace.com) (www.biospace.com). Following the late-2025 trial results (discussed below), the company moved to tighten its belt. Management announced immediate cost reductions in pre-commercial and manufacturing activities to conserve cash, given the outcome of the trials (www.mereobiopharma.com). With these adjustments, Mereo updated its guidance that its cash balance (~$41 million at year-end 2025) should fund the company into mid-2027 (simplywall.st) (simplywall.st). This relatively long runway (about 1.5 years beyond prior expectations) reflects sharp spending cuts and the shelving or slow-rolling of certain expenses after the trial setback.

It’s important to note that the cash runway is an estimate, not a guarantee. It assumes no major new clinical trials are started without additional funding. Mereo still plans to conduct a Phase 3 trial for its other lead program (alvelestat in alpha-1 antitrypsin deficiency lung disease), but that trial is expected to be partnered or otherwise externally funded (www.biospace.com). In the absence of partnership capital, a trial of that scale would quickly consume Mereo’s cash. Investors should monitor Mereo’s quarterly cash burn and any deal announcements to gauge if the mid-2027 runway projection remains realistic.

Valuation and Peer Comparison

Market Value vs Book Value: Mereo’s share price has suffered a steep decline over the past year due to clinical uncertainties. As of mid-January 2026, MREO was trading around $0.64 per share (ADR) (simplywall.st). This price reflects a dramatic drop – roughly –66% over the prior 30 days and –78% over the past year (simplywall.st), underscoring how much investor sentiment worsened after the recent trial results. At $0.64, Mereo’s market capitalization is approximately $80 million. By comparison, the company’s net assets (book value) are around $36 million, implying a Price-to-Book (P/B) ratio of ~2.2× (simplywall.st).

This P/B multiple suggests that MREO trades at a slight discount to the broad U.S. biotech industry average P/B of ~2.6×, but at a premium relative to closer peers in the small-cap biotech space (peer average ~1.4× P/B) (simplywall.st). In other words, the stock isn’t the absolute cheapest in terms of book value, as investors are still assigning some premium for Mereo’s pipeline potential and cash on hand. However, given the lack of profitability, P/B is just one lens – it basically tells us Mereo’s market value is about 2.2 times its accountants’ equity, which largely consists of its cash balance and acquired intangibles.

Priced for Uncertainty: A P/B above 2×, even after recent declines, indicates that the market still attributes meaningful value to Mereo’s pipeline and intangibles beyond the current cash. The company’s two core clinical assets (setrusumab and alvelestat) and other partnered programs presumably justify this premium over pure liquidation value. It’s worth noting that sell-side analysts had price targets clustered around $3.00 prior to the trial readout (simplywall.st), reflecting much higher expected value if the lead program succeeded. With the stock under $1 now, the market has drastically reset expectations, pricing in a high probability of failure or delay.

Traditional valuation metrics like P/E or EV/EBITDA are not applicable since Mereo has no earnings and negative EBITDA. Instead, investors value MREO on pipeline potential, partnership milestones, and cash runway. One way to frame the current valuation is to compare it to cash: at $0.64/share, the enterprise value (market cap minus cash) is on the order of $40 million. For that $40 million, investors get Mereo’s pipeline assets and partnerships (the “pipeline optionality”). Whether that is cheap or expensive depends on one’s view of the pipeline’s chances after recent events. A Simply Wall St analysis, for example, opined that Mereo’s valuation is roughly fair on a P/B basis – not obviously a bargain relative to peers, but not wildly overpriced either (simplywall.st) (simplywall.st). The wide range of community fair value estimates (from ~$1.22 up to $12 per share according to one source) highlights the uncertainty and divergent opinions on the stock’s true worth (simplywall.st).

In summary, MREO’s current valuation reflects tempered expectations. The stock is trading near multi-year lows, indicating that the market has “priced in” the recent pipeline setback and then some. If the company’s fortunes improve (e.g. a new partnership or a path forward for setrusumab emerges), there could be significant upside from these levels. Conversely, the downside risk is that even the remaining ~$0.64 price could erode further if the company’s pipeline disappoints again or if it dilutes shareholders with fundraising. Investors are effectively betting on the management’s ability to extract value from the pipeline with the cash at hand.

Key Risks and Red Flags

Mereo BioPharma faces elevated risks typical of a late-clinical-stage biotech, now compounded by recent events and investor actions. Below we outline major risks and red flags:

- Lead Program Setback: The much-anticipated Phase 3 results for Mereo’s lead candidate setrusumab (for Osteogenesis Imperfecta) were largely negative. Neither the adult ORBIT study nor the pediatric COSMIC study met their primary endpoint of reducing fracture rates versus control (www.mereobiopharma.com). While both trials showed improvements in a secondary endpoint (bone density), the failure to hit the key fracture reduction goals is a serious blow to the drug’s approval prospects. This outcome removes what was the nearest-term catalyst for Mereo and casts doubt on a program that investors had been counting on. The stock’s steep decline (–66% in one month) reflects this disappointment (simplywall.st). The risk now is that setrusumab might never achieve regulatory approval or commercial success, especially if partner Ultragenyx decides to scale back or terminate development after reviewing the data. This uncertainty around the flagship program is the single biggest risk to Mereo’s valuation.

- Securities Class Action Lawsuit: In early 2026, following the trial disclosures, a shareholder class action was filed alleging that Mereo misled investors about the prospects of the setrusumab trials (www.globenewswire.com) (www.globenewswire.com). According to the complaint, Mereo’s management had expressed confidence that setrusumab would reduce fractures and meet the primary endpoint, while allegedly concealing adverse facts – namely, that internal data did not support those optimistic claims and that the trials ultimately failed their primary endpoints (www.globenewswire.com). When the truth came out on December 29, 2025, the stock plummeted, causing investor losses. The lawsuit claims these losses are attributable to the company’s false or misleading statements (www.globenewswire.com). Legal proceedings are at an early stage: investors have until April 6, 2026 to seek lead-plaintiff status in the case (www.globenewswire.com). While such lawsuits against biotech firms are not uncommon after trial failures, they pose a reputational and financial risk. Potential outcomes range from dismissal of the case to a settlement or judgment costing Mereo a significant sum (often covered by D&O insurance, but still a distraction). At minimum, the allegations highlight a governance red flag – implying management may have been overly promotional or lacked full transparency with investors.

- Regulatory and Clinical Risk: Even beyond setrusumab, Mereo’s pipeline faces the usual clinical development risks. The next major asset, alvelestat (for alpha-1 antitrypsin deficiency lung disease), is heading into Phase 3. While Phase 2 results were encouraging enough to attract potential partners, there is no guarantee the Phase 3 will succeed. Any single trial failure can derail the program and cripple the stock further. Additionally, regulatory approval, especially for rare disease drugs, can be unpredictable – endpoints and data that seem favorable may not meet regulatory standards. Mereo’s partnered programs (e.g. an oncology antibody etigilimab, and others out-licensed) also carry risk that partners might discontinue development if results underwhelm.

- Financing and Dilution Risk: Mereo will require additional capital to fully execute its development plans. The company has been forthright that its cash, while extending into mid-2027 at current burn rates (simplywall.st) (simplywall.st), is not enough to commercialize its programs without external funding. Management explicitly states it will seek “non-dilutive funding, equity or debt financings” as needed (www.sec.gov) (www.sec.gov). If partnerships (non-dilutive capital) don’t come through, Mereo may resort to dilutive equity raises or additional debt. Given the low share price, any sizable equity offering could significantly dilute existing shareholders and pressure the stock. The convertible notes outstanding also represent potential dilution – conversion of the remaining £6.2 million notes will add to share count (albeit much is likely already factored in). In short, financing risk is high, and investors face uncertain dilution over the next 1–2 years.

- Nasdaq Compliance & Liquidity: MREO’s ADS is once again trading below the Nasdaq $1.00 minimum bid price requirement (simplywall.st). The company previously fell out of compliance in late 2022 when shares traded under $1, but it regained compliance by May 2023 after its stock price improved above $1 for 10 consecutive days (www.mereobiopharma.com). Now, after the late-2025 drop, MREO closed at ~$0.64 – raising the risk of another Nasdaq deficiency notice if the price doesn’t recover. Being a sub-$1 “penny stock” also hurts liquidity and investor perception, and in a worst case could lead to delisting from Nasdaq (forcing OTC trading) if not corrected. Mereo may need to consider measures like a reverse stock split to cure a bid-price deficiency should the stock not organically rebound above $1 in the coming months. This is a risk to monitor in 2026.

- Shareholder Activism and Governance Concerns: Mereo’s management has a recent history of conflict with significant shareholders. In 2022, an activist investor (Rubric Capital, 14% owner) launched a proxy fight, accusing Mereo’s board of lacking a “credible plan to create value” and essentially just “doing nothing; waiting and hoping for the best” (www.biospace.com). The battle resulted in a settlement that ousted four board members and added Rubric’s nominees, reflecting serious prior governance issues. While the proxy fight was settled, the underlying concerns – e.g. whether management is optimally allocating capital and pursuing the right strategy – remain salient. The presence of activists can be a double-edged sword: they may push for value creation (e.g. demanding asset sales or M&A), but also signal that insiders’ strategic judgment was questioned. Going forward, there’s a risk of renewed activist pressure if the stock remains depressed. Shareholders should be aware that governance risk is higher here than in a typical company, given this history.

- Intangible Asset Risk & Potential Impairments: A more accounting-related red flag: Mereo’s balance sheet likely contains intangible assets or goodwill from earlier acquisitions (for example, the 2019 reverse merger with OncoMed Pharmaceuticals and asset purchases from Novartis/AstraZeneca). If the associated programs (like setrusumab, derived from Novartis) fail or are discontinued, Mereo may need to write down these intangibles, increasing reported losses. While impairments are non-cash charges, they would underscore the destruction of invested capital. Any such write-downs could further erode book value and potentially breach covenants (though Mereo has no traditional debt covenants in play).

In summary, Mereo faces a confluence of risks: clinical failure of its lead drug, a brewing legal battle, funding needs, stock price compliance issues, and prior governance turmoil. Each of these factors could negatively impact shareholders if not managed well. Potential investors in MREO should have a high risk tolerance and closely follow developments on all these fronts.

Open Questions and Outlook

Given the challenges outlined, several open questions hover over Mereo BioPharma’s future. These unanswered questions will shape whether the stock is a turnaround story or a value trap:

- Can Setrusumab Be Salvaged? – With the Phase 3 fracture endpoint missed, what is the fate of setrusumab (UX143) in osteogenesis imperfecta? Mereo and its partner Ultragenyx are conducting additional analyses on the trial data to assess next steps, especially in pediatric patients (www.mereobiopharma.com). There were hints of a fracture-rate reduction trend in children (COSMIC study) despite not reaching statistical significance (www.mereobiopharma.com) (www.mereobiopharma.com). Will regulators entertain an approval or conditional approval based on secondary endpoints (like bone density gains) or subgroup data? Or could a redesigned trial focusing on pediatrics succeed where the prior studies didn’t? These questions are critical – if a viable path forward for setrusumab emerges (for example, a new trial or an extension study), it could restore some of the drug’s lost value. Conversely, if Ultragenyx walks away or if further analysis confirms no real efficacy, Mereo might have to write off this program. Investors are awaiting guidance on this from management in coming quarters.

- Will Alvelestat Get a Partner or Go Solo? – Mereo’s next lead program is alvelestat (an oral therapy for Alpha-1 Antitrypsin Deficiency lung disease). The plan is to initiate a single, global Phase 3 trial, and management has been “actively engaged with multiple potential partners” to fund and co-develop alvelestat (www.biospace.com). An open question is whether Mereo can secure a partnership deal on favorable terms. A partnership could bring upfront cash and offload trial costs (similar to how the Ultragenyx deal funded setrusumab’s Phase 3). However, if a partner doesn’t materialize, will Mereo attempt to finance and run the Phase 3 alone? Doing so would be extremely cash-intensive – likely far beyond its current $41 million reserve. The company might then face a tough choice: raise a large amount of capital (diluting shareholders) or shelve the program. The outcome of partnership negotiations will significantly impact Mereo’s strategy and cash needs in 2026–2027.

- What’s the Game Plan for Other Assets? – Beyond its two lead programs, Mereo has other assets in the pipeline or partnered out. For instance, etigilimab (an anti-TIGIT antibody for cancer) was in Phase 1 and became part of Mereo via the OncoMed merger; its status is currently unclear (no recent mention, possibly deprioritized). Vantictumab, a Wnt-pathway antibody, was out-licensed in 2025 to ōAshibi (retaining EU rights) for a rare bone disorder (www.biospace.com). Leflutrozole for infertility was licensed to a partner (ReproNovo) in 2022 for milestones up to ~$64 million (though those are contingent on development progress) (www.sec.gov). The open question is whether these peripheral programs can generate non-dilutive value. Will Mereo receive any milestones or royalties from partners in the foreseeable future? And, strategically, should Mereo monetize or divest some assets to focus on its core and raise cash? For example, now that vantictumab is with a partner, Mereo might eventually sell its European rights if that drug shows promise – providing a cash infusion. Clarity on the fate and focus of these non-core programs is needed.

- How Will the Class Action Resolve? – The shareholder lawsuit will likely take time to play out. An open question is whether Mereo’s management will make any changes in response. Often, such suits get settled out of court with no admission of wrongdoing, for an amount covered largely by insurance. However, if the case uncovers troubling communications or actions (for example, internal data showing trial issues that were withheld), it could pressure Mereo’s leadership. Will there be any management turnover or board changes stemming from this? Investors will watch for any signs of governance change, as well as the financial impact (any settlement or litigation expense). While the lawsuit is a background issue for now, its progression bears watching, especially given Mereo’s previous run-in with activists criticizing transparency.

- Can Management Restore Trust? – Mereo’s CEO (Dr. Denise Scots-Knight) and team are now tasked with navigating the company through this difficult stretch. Investor trust has been shaken – not only by the trial failure but by the perception (alleged in the lawsuit and by activists) that management may have been overpromising and under-delivering (www.globenewswire.com) (www.biospace.com). An open question is whether management can regain credibility. This could happen through straightforward, reality-based communication and by executing on a refocused plan (e.g. securing a partner for alvelestat, cutting unnecessary spending, etc.). Alternatively, it’s possible that new leadership or board refresh could occur if major shareholders lose patience. The proxy fight in 2022 showed that investors are willing to force changes at Mereo. A year or two from now, will we see the same CEO and strategy in place, or a substantially revamped approach? The answer will influence market sentiment.

- Is Mereo a Takeover or Merger Candidate? – Given Mereo’s low valuation and surplus cash relative to its market cap, one open question is whether the company becomes a target for M&A or a reverse merger. Small biotechs that suffer a trial failure sometimes merge with another biotech (to utilize the cash and listing) or get acquired for remaining assets on the cheap. With around $40 million EV and a Nasdaq listing, Mereo could be attractive to a private biotech seeking a public entry or to a strategic buyer interested in alvelestat or the shell for financial reasons. The Rubric activist campaign previously pushed for considering strategic alternatives (like asset sales). Now that setrusumab’s outcome is known, will Mereo explore a merger or sale? Thus far, management has not indicated an intent to pivot into a shell or seek a buyer – they seem focused on continuing development. But as time passes, if the stock languishes, pressure could mount to consider a strategic transaction. This remains an open-ended scenario.

Outlook: In the near term, Mereo is in damage-control and transition mode. The company’s CEO stated, “we are carefully managing our cash resources…with immediate reductions in pre-commercial activities, and continuing to advance partnering discussions for alvelestat” (www.mereobiopharma.com). This signals a leaner operation laser-focused on extracting value from the remaining pipeline. For investors, the story will likely pivot around alvelestat’s progress and any new partnerships in 2026, as well as any updates on a possible narrower path for setrusumab (e.g. pediatric use). The class action lawsuit and any further activist involvement will form part of the backdrop, potentially catalyzing changes or at least volatility.

In summary, Mereo BioPharma’s situation is high-risk, high-reward. The upcoming deadlines (legal and clinical) urge investors to “act now” in the sense of staying informed and making careful decisions. With the lead asset’s failure, the company must chart a new course – either by salvaging what it can, pivoting to its other program, or perhaps engaging in strategic deals. Whether current shareholders will see significant recovery or further decline hinges on how these open questions are resolved in the coming months. Each development – be it a partnership announcement, a legal resolution, or a clinical plan update – could materially swing MREO’s valuation. Investors should monitor news closely as the deadline for class action counsel approaches and as Mereo’s management works to rebuild the company’s trajectory under intense scrutiny.

Sources:

- Mereo BioPharma 2022 Annual Report on Form 20-F (SEC filing) (www.sec.gov) (www.sec.gov) (www.sec.gov) (www.sec.gov) - Mereo BioPharma Q3 2025 Results & Corporate Update (www.biospace.com) (www.biospace.com) (www.biospace.com) - Mereo BioPharma Press Release, Phase 3 ORBIT and COSMIC Results for Setrusumab (Dec. 29, 2025) (www.mereobiopharma.com) (www.mereobiopharma.com) - Simply Wall St analysis of Mereo (Jan. 2026) (simplywall.st) (simplywall.st) (simplywall.st) - Rosen Law Firm press release (Feb. 13, 2026) detailing class action allegations (www.globenewswire.com) (www.globenewswire.com) - BioSpace news articles on Mereo’s proxy battle settlement (Oct. 2022) (www.biospace.com) and other investor communications.